CTLA4 and neoplasm: The peri-tumoral injections of anti-PD-L1- PlGF-2123-144 plus anti-CTLA-4- PlGF-2123-144 can induce the tumor-infiltrating T cells, leading to the tumor suppression and increase the survival rate (Ishihara et al., 2017[21]).